18-51076682-G-GGCTACTGCACAAGCTGCAGCAGCTGCCC
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_005359.6(SMAD4):c.1354_1381dupGCTACTGCACAAGCTGCAGCAGCTGCCC(p.Gln461fs) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 32)
Consequence
SMAD4
NM_005359.6 frameshift
NM_005359.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 9.83
Genes affected
SMAD4 (HGNC:6770): (SMAD family member 4) This gene encodes a member of the Smad family of signal transduction proteins. Smad proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor (TGF)-beta signaling. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and recognizes an 8-bp palindromic sequence (GTCTAGAC) called the Smad-binding element (SBE). The protein acts as a tumor suppressor and inhibits epithelial cell proliferation. It may also have an inhibitory effect on tumors by reducing angiogenesis and increasing blood vessel hyperpermeability. The encoded protein is a crucial component of the bone morphogenetic protein signaling pathway. The Smad proteins are subject to complex regulation by post-translational modifications. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia syndrome. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 18-51076682-G-GGCTACTGCACAAGCTGCAGCAGCTGCCC is Pathogenic according to our data. Variant chr18-51076682-G-GGCTACTGCACAAGCTGCAGCAGCTGCCC is described in ClinVar as [Pathogenic]. Clinvar id is 188177.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMAD4 | NM_005359.6 | c.1354_1381dupGCTACTGCACAAGCTGCAGCAGCTGCCC | p.Gln461fs | frameshift_variant | 11/12 | ENST00000342988.8 | NP_005350.1 | |
SMAD4 | NM_001407041.1 | c.1354_1381dupGCTACTGCACAAGCTGCAGCAGCTGCCC | p.Gln461fs | frameshift_variant | 11/12 | NP_001393970.1 | ||
SMAD4 | NM_001407042.1 | c.1354_1381dupGCTACTGCACAAGCTGCAGCAGCTGCCC | p.Gln461fs | frameshift_variant | 11/12 | NP_001393971.1 | ||
SMAD4 | NR_176265.1 | n.1892_1919dupGCTACTGCACAAGCTGCAGCAGCTGCCC | non_coding_transcript_exon_variant | 11/13 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMAD4 | ENST00000342988.8 | c.1354_1381dupGCTACTGCACAAGCTGCAGCAGCTGCCC | p.Gln461fs | frameshift_variant | 11/12 | 5 | NM_005359.6 | ENSP00000341551.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 30
GnomAD4 exome
Cov.:
30
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Generalized juvenile polyposis/juvenile polyposis coli Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 25, 2014 | This sequence change inserts 28 nucleotides in exon 11 of the SMAD4 mRNA (c.1352_1354ins28), causing a frameshift at codon 461. This creates a premature translational stop signal (p.Gln461Argfs*42) and is expected to result in an absent or disrupted protein product. While this particular sequence change has not been reported in the literature, truncating sequence changes in SMAD4 are known to be pathogenic (PMID: 22810475). A different 28bp duplication in exon 11 has been reported in a patient with juvenile polyposis syndrome (JPS) (PMID: 23239472). For these reasons, this sequence change has been classified as Pathogenic. - |
Juvenile polyposis syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 25, 2014 | A different 28bp duplication in exon 11 has been reported in a patient with juvenile polyposis syndrome (JPS) (PMID: 23239472). For these reasons, this sequence change has been classified as Pathogenic. While this particular sequence change has not been reported in the literature, truncating sequence changes in SMAD4 are known to be pathogenic (PMID: 22810475). This sequence change inserts 28 nucleotides in exon 11 of the SMAD4 mRNA (c.1352_1354ins28), causing a frameshift at codon 461. This creates a premature translational stop signal (p.Gln461Argfs*42) and is expected to result in an absent or disrupted protein product. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at